| Abstrakt: |
A recent study conducted by the University of Texas MD Anderson Cancer Center examined the use of subgroup analyses in phase 3 oncology trials from 2004 to 2020. Subgroup analyses are often used to investigate differential treatment effects in oncology and may influence regulatory approvals. The study found that nearly half of the trials included a subgroup analysis, but many of these analyses lacked essential features for interpretation. Additionally, most of the claims regarding differential treatment effects were not supported. The researchers concluded that caution should be exercised when interpreting oncology subgroup analyses, and improvements to their quality are necessary. [Extracted from the article] |
